{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:06:48Z","timestamp":1760954808282},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1093\/jac\/dki392","type":"journal-article","created":{"date-parts":[[2005,11,25]],"date-time":"2005-11-25T01:33:23Z","timestamp":1132882403000},"page":"991-995","source":"Crossref","is-referenced-by-count":7,"title":["Chronic hepatitis C in patients with HIV\/AIDS: a new challenge in antiviral therapy"],"prefix":"10.1093","volume":"56","author":[{"given":"Norbert","family":"Br\u00e4u","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,12]]},"reference":[{"key":"key\n\t\t\t\t20171010141609_B1","doi-asserted-by":"crossref","unstructured":"Giordano TP, Kramer JR, Souchek J et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med2004; 164: 2349\u201354.","DOI":"10.1001\/archinte.164.21.2349"},{"key":"key\n\t\t\t\t20171010141609_B2","doi-asserted-by":"crossref","unstructured":"Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology2005; 41: 779\u201389.","DOI":"10.1002\/hep.20626"},{"key":"key\n\t\t\t\t20171010141609_B3","doi-asserted-by":"crossref","unstructured":"Kramer JR, Giordano TP, Souchek J et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol2005; 42: 309\u201314.","DOI":"10.1016\/j.jhep.2004.11.017"},{"key":"key\n\t\t\t\t20171010141609_B4","doi-asserted-by":"crossref","unstructured":"El Serag HB, Giordano TP, Kramer J et al. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol2005; 3: 175\u201383.","DOI":"10.1016\/S1542-3565(04)00620-2"},{"key":"key\n\t\t\t\t20171010141609_B5","unstructured":"Br\u00e4u N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2005, in press (online publication 20 September 2005)."},{"key":"key\n\t\t\t\t20171010141609_B6","doi-asserted-by":"crossref","unstructured":"Saillour F, Dabis F, Dupon M et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. BMJ1996; 313: 461\u20134.","DOI":"10.1136\/bmj.313.7055.461"},{"key":"key\n\t\t\t\t20171010141609_B7","doi-asserted-by":"crossref","unstructured":"Br\u00e4u N, Rodriguez-Torres M, Prokupek D et al. Treatment of chronic hepatitis C in HIV\/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology2004; 39: 989\u201398.","DOI":"10.1002\/hep.20107"},{"key":"key\n\t\t\t\t20171010141609_B8","doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Felizarta F, Smith C et al. Daily versus thrice-weekly interferon Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr2004; 35: 464\u201372.","DOI":"10.1097\/00126334-200404150-00004"},{"key":"key\n\t\t\t\t20171010141609_B9","doi-asserted-by":"crossref","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med2004; 351: 438\u201350.","DOI":"10.1056\/NEJMoa040842"},{"key":"key\n\t\t\t\t20171010141609_B10","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975\u201382.","DOI":"10.1056\/NEJMoa020047"},{"key":"key\n\t\t\t\t20171010141609_B11","doi-asserted-by":"crossref","unstructured":"Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med2004; 351: 451\u20139.","DOI":"10.1056\/NEJMoa032653"},{"key":"key\n\t\t\t\t20171010141609_B12","doi-asserted-by":"crossref","unstructured":"Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA2004; 292: 2839\u201348.","DOI":"10.1001\/jama.292.23.2839"},{"key":"key\n\t\t\t\t20171010141609_B13","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958\u201365.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"key\n\t\t\t\t20171010141609_B14","doi-asserted-by":"crossref","unstructured":"Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients. AIDS2004; 18: F27\u2013F36.","DOI":"10.1097\/00002030-200409030-00003"},{"key":"key\n\t\t\t\t20171010141609_B15","doi-asserted-by":"crossref","unstructured":"Hadziyannis SJ, Sette H, Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med2004; 140: 346\u201355.","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"key\n\t\t\t\t20171010141609_B16","doi-asserted-by":"crossref","unstructured":"Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection. Lancet2001; 357: 280\u20131.","DOI":"10.1016\/S0140-6736(00)03618-7"},{"key":"key\n\t\t\t\t20171010141609_B17","doi-asserted-by":"crossref","unstructured":"Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis2004; 38: e79\u2013e80.","DOI":"10.1086\/383151"},{"key":"key\n\t\t\t\t20171010141609_B18","unstructured":"Br\u00e4u N, Torriani FJ, Rockstroh J et al. Safety of peginterferon alfa-2a (PEGASYS) 180 mcg weekly plus ribavirin (RBV) 800 mg daily in HIV\/HCV coinfection compared to HCV monoinfection [Abstract]. In: XV International AIDS Conference, Bangkok, 2004. Abstract No MoPeB3311, p 178."},{"key":"key\n\t\t\t\t20171010141609_B19","doi-asserted-by":"crossref","unstructured":"Rodriguez-Torres M, Torriani FJ, Soriano V et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV\/HIV co-infection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49: 3997\u20134008.","DOI":"10.1128\/AAC.49.10.3997-4008.2005"},{"key":"key\n\t\t\t\t20171010141609_B20","doi-asserted-by":"crossref","unstructured":"Lane HC, Davey V, Kovacs JA et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med1990; 112: 805\u201311.","DOI":"10.7326\/0003-4819-112-11-805"},{"key":"key\n\t\t\t\t20171010141609_B21","doi-asserted-by":"crossref","unstructured":"Sherman KE, Shire NJ, Rouster SD et al. Viral kinetics in hepatitis C or hepatitis C\/human immunodeficiency virus-infected patients. Gastroenterology2005; 128: 313\u201327.","DOI":"10.1053\/j.gastro.2004.11.059"},{"key":"key\n\t\t\t\t20171010141609_B22","doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Dieterich DT, Bini EJ et al. Epoetin alfa once weekly improves anemia in HIV\/hepatitis C virus-coinfected patients treated with interferon\/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr2005; 39: 504\u20136.","DOI":"10.1097\/01.qai.0000167158.90722.73"},{"key":"key\n\t\t\t\t20171010141609_B23","doi-asserted-by":"crossref","unstructured":"Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med2000; 132: 517\u201324.","DOI":"10.7326\/0003-4819-132-7-200004040-00002"},{"key":"key\n\t\t\t\t20171010141609_B24","unstructured":"Afdhal NH, Godofski E, Dienstag J et al. Final phase I\/II trial results for NM283, a new polymerase inhibitor for hepatitis C (Abstract). Hepatology2004; 40 Suppl 1: 726."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/6\/991\/2259804\/dki392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T05:47:17Z","timestamp":1586584037000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/6\/991\/753039\/Chronic-hepatitis-C-in-patients-with-HIVAIDS-a-new"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,12]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki392","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,12]]},"published":{"date-parts":[[2005,12,1]]}}}